| Serial Number | 88830833 |
| Word Mark | TRIVAIR |
| Filing Date | Wednesday, March 11, 2020 |
| Status | 651 - SUSPENSION INQUIRY - MAILED |
| Status Date | Wednesday, January 14, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| Goods and Services | Inhalers filled with pharmaceutical preparations for use in the treatment of respiratory diseases, disorders and infections; inhalers filled with pharmaceutical preparations for use in the treatment of asthma; inhalers filled with pharmaceutical preparations for use in the treatment of chronic obstructive pulmonary disease; inhalers filled with pharmaceutical preparations for use in the treatment of rhinitis; inhalers filled with pharmaceutical preparations for use in the treatment of sinus polyps; inhalers filled with pharmaceutical preparations for use in the treatment of viral airway infections; inhalers filled with pharmaceutical preparations for use in the treatment of multiple sclerosis; inhalers filled with pharmaceutical preparations for use in the treatment of depression; inhalers filled with pharmaceutical preparations for use in the treatment of epilepsy; inhalers filled with pharmaceutical preparations for use in the treatment of migraine; inhalers filled with pharmaceutical preparations for use in the treatment of Alzheimer's disease; inhalers filled with pharmaceutical preparations for use in the treatment of Parkinson's disease; inhalers filled with pharmaceutical preparations for use in the treatment of cerebrovascular accident or stroke; inhalers filled with pharmaceutical preparations for use in the treatment of traumatic brain injury; inhalers filled with pharmaceutical preparations for use in the treatment of cancer; inhalers filled with pharmaceutical preparations for use in the treatment of nausea; inhalers filled with pharmaceutical preparations for use in the treatment of post-traumatic stress disorder; inhalers filled with pharmaceutical preparations for use in the treatment of amyotrophic lateral sclerosis; inhalers filled with pharmaceutical preparations for use in the treatment of chronic pain; inhalers filled with pharmaceutical preparations for use in the treatment of insomnia; inhalers filled with pharmaceutical preparations for use in the relief of pain; inhalers filled with pharmaceutical preparations for use in the treatment of cough or sore throat; inhalers filled with pharmaceutical preparations for use in the treatment of candida infection; inhalers filled with pharmaceutical preparations for use in anti-fungal treatment; inhalers filled with pharmaceutical preparations for use in sedation; inhalers filled with pharmaceutical preparations for use in hormone replacement therapy; inhalers filled with pharmaceutical preparations for use in the treatment of psychosis; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of respiratory diseases, disorders and infections; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of asthma; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of chronic obstructive pulmonary disease; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of rhinitis; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of sinus polyps; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of viral airway infections; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of multiple sclerosis; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of depression; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of epilepsy; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of migraine; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of Alzheimer's disease; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of Parkinson's disease; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of cerebrovascular accident or stroke; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of traumatic brain injury; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of cancer; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of nausea; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of post-traumatic stress disorder; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of amyotrophic lateral sclerosis; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of chronic pain; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of insomnia; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the relief of pain; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of cough or sore throat; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of candida infection; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in anti-fungal treatment; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in sedation; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in hormone replacement therapy; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of psychosis; inhalers used to deliver therapeutic agents, namely, analgesics, sedatives, vaccines, anesthetics, insulin, antiemetics, antifungals, hormones, or antipsychotics; drug delivery devices, namely, breath actuated nasal delivery devices used to deliver therapeutic agents, namely, analgesics, sedatives, vaccines, anesthetics, insulin, antiemetics, antifungals, hormones, or antipsychotics; inhalers filled with analgesics, sedatives, vaccines, anesthetics, insulin, antiemetics, antifungals, hormones, respiratory therapeutic agents, or antipsychotics; drug delivery devices, namely, breath actuated nasal delivery devices filled with analgesics, sedatives, vaccines, anesthetics, insulin, antiemetics, antifungals, hormones, respiratory therapeutic agents, or antipsychotics; none of the foregoing containing cannabis or CBD |
| Goods and Services | Medical apparatus and instruments, namely, inhalers, sold empty, for therapeutic use; medical apparatus and instruments, namely, breath actuated nasal drug delivery devices, sold empty, for therapeutic use; none of the foregoing for use with cannabis or CBD |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, March 18, 2020 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials. |
| US Class Codes | 026, 039, 044 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, March 18, 2020 |
| Primary Code | 010 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Acerus Biopharma Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Mississauga, Ontario L5L1J9 CA |
| Event Date | Event Description |
| Saturday, March 14, 2020 | NEW APPLICATION ENTERED |
| Wednesday, March 18, 2020 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, June 2, 2020 | ASSIGNED TO EXAMINER |
| Wednesday, June 17, 2020 | ASSIGNED TO EXAMINER |
| Monday, September 14, 2020 | ASSIGNED TO EXAMINER |
| Monday, September 14, 2020 | NON-FINAL ACTION WRITTEN |
| Monday, September 14, 2020 | NON-FINAL ACTION E-MAILED |
| Monday, September 14, 2020 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, January 5, 2021 | EXAMINERS AMENDMENT -WRITTEN |
| Tuesday, January 5, 2021 | EXAMINERS AMENDMENT E-MAILED |
| Tuesday, January 5, 2021 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Tuesday, January 5, 2021 | EXAMINER'S AMENDMENT ENTERED |
| Friday, January 8, 2021 | SUSPENSION LETTER WRITTEN |
| Friday, January 8, 2021 | LETTER OF SUSPENSION E-MAILED |
| Friday, January 8, 2021 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Wednesday, September 1, 2021 | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION |
| Tuesday, October 5, 2021 | SUSPENSION INQUIRY WRITTEN |
| Tuesday, October 5, 2021 | INQUIRY TO SUSPENSION E-MAILED |
| Tuesday, October 5, 2021 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED |
| Tuesday, May 3, 2022 | ASSIGNED TO EXAMINER |
| Tuesday, May 3, 2022 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
| Tuesday, May 3, 2022 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND |
| Tuesday, May 3, 2022 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
| Monday, May 9, 2022 | TEAS PETITION TO REVIVE RECEIVED |
| Monday, May 9, 2022 | PETITION TO REVIVE-GRANTED |
| Monday, May 9, 2022 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, May 10, 2022 | NOTICE OF REVIVAL - E-MAILED |
| Wednesday, May 11, 2022 | ASSIGNED TO LIE |
| Wednesday, May 18, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, May 18, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, May 18, 2022 | SUSPENSION LETTER WRITTEN |
| Wednesday, May 18, 2022 | LETTER OF SUSPENSION E-MAILED |
| Wednesday, May 18, 2022 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Friday, October 28, 2022 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Friday, October 28, 2022 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Friday, October 28, 2022 | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS |
| Friday, October 28, 2022 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Tuesday, November 15, 2022 | SUSPENSION INQUIRY WRITTEN |
| Tuesday, November 15, 2022 | INQUIRY TO SUSPENSION E-MAILED |
| Tuesday, November 15, 2022 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED |
| Monday, May 15, 2023 | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED |
| Tuesday, January 30, 2024 | ASSIGNED TO LIE |
| Tuesday, January 30, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, January 30, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, February 2, 2024 | ASSIGNED TO EXAMINER |
| Wednesday, February 7, 2024 | SUSPENSION LETTER WRITTEN |
| Wednesday, February 7, 2024 | LETTER OF SUSPENSION E-MAILED |
| Wednesday, February 7, 2024 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Friday, December 27, 2024 | SUSPENSION INQUIRY WRITTEN |
| Friday, December 27, 2024 | INQUIRY TO SUSPENSION E-MAILED |
| Friday, December 27, 2024 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED |
| Thursday, March 13, 2025 | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED |
| Friday, March 14, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, March 14, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, March 14, 2025 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Sunday, March 16, 2025 | SUSPENSION LETTER WRITTEN |
| Sunday, March 16, 2025 | LETTER OF SUSPENSION E-MAILED |
| Sunday, March 16, 2025 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Wednesday, September 17, 2025 | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION |
| Wednesday, January 14, 2026 | SUSPENSION INQUIRY WRITTEN |
| Wednesday, January 14, 2026 | INQUIRY TO SUSPENSION E-MAILED |
| Wednesday, January 14, 2026 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED |